Market Trends– category –
-
Dexcom Stelo Wins FDA Approval as First Prescription-Free OTC Continuous Glucose Monitor for Non-Insulin Users
Dexcom (via Facebook) USA Overview Dexcom's Stelo glucose biosensor system has received FDA approval as the first over-the-counter (OTC) continuous glucose monitor (CGM) for adults aged 18 and older who do not use insulin. This landmark ... -
Maravai LifeSciences Sustains Revenue Outlook in Q2, Strategically Reinforces TriLink’s mRNA, CDMO, and Specialty Chemistry Focus
TradingView USA Overview Maravai LifeSciences confirmed its Q2 revenue guidance, demonstrating resilience amidst fluctuations in large-scale CDMO projects and GMP consumables. The company reported consistent growth in smaller and mid-siz... -
EU to Introduce New 1-Year End-Use Threshold for Microplastic Exemption Under REACH Regulation by 2028
IRTS Lab EU Overview The OECD Test Guideline 318, relevant for polymeric nanomaterials, specifies dispersity, stability, and degradation testing for polymer particles ranging from 1 nm to 1 µm. This guideline is crucial for REACH complia... -
Smoltek and Heraeus Launch Critical 3,000-Hour Durability Test for Ultra-Low Iridium PEM Electrolyzers
Smoltek Nanotech Holding AB Sweden Overview Smoltek Hydrogen and Heraeus Precious Metals are intensifying their joint efforts to develop next-generation, ultra-low iridium Porous Transport Electrodes (PTEs) for Proton Exchange Membrane (... -
UKRI Annual Report: Concretene’s Graphene-Enhanced Concrete Reduces Embodied Carbon by 20-30%, Driving Construction Decarbonization
UKRI UK Overview The UKRI (UK Research and Innovation) annual report highlights Concretene, a Manchester-based nanotechnology firm, which developed an innovative graphene-enhanced concrete admixture. This technology has the potential to ... -
Merck Expands Singapore BioReliance Lab with Asia Pacific’s First Cell Line Characterization and GMP NGS Capabilities
BioPharma APAC Singapore Overview Merck is expanding its Singapore BioReliance lab to strengthen analytical and biosafety testing services in the Asia Pacific region. The expanded facility will offer the first BioReliance Cell Line Chara... -
Rapid Rise of iPSC-Based Therapies: Manufacturing Challenges and FUJIFILM Cellular Dynamics’ Automation Solutions
Contract Pharma International Overview iPSC-based therapies are rapidly advancing as a renewable, standardized source for allogeneic treatments and scalable solutions across various indications. However, manufacturing poses challenges in... -
Building Commercial Readiness in Advanced Therapies: Optimizing Supply Chain, Manufacturing, and Regulatory Strategy is Critical
The Medicine Maker Unknown Overview Achieving commercial readiness for Advanced Therapy Medicinal Products (ATMPs), particularly cell and gene therapy products, is an urgent industry imperative. This requires establishing robust supply c... -
CGT Manufacturers Transform Regulatory Demands into Innovation Drivers: New Strategies for Enhanced Quality and Efficiency
MasterControl USA Overview Cell and gene therapy (CGT) manufacturers are adopting new strategies to leverage stringent regulatory requirements as opportunities for innovation and quality improvement, rather than mere obstacles. Central t... -
CDMO Capacity Crunch Persists in Cell and Gene Therapy Sector: Strategic Partnerships Crucial for Accelerating Innovation
Contract Pharma USA Overview The cell and gene therapy (CGT) sector faces a severe and persistent capacity crunch among Contract Development and Manufacturing Organizations (CDMOs), driven by soaring demand. This bottleneck significantly...
